Ian H Gilbert
Overview
Explore the profile of Ian H Gilbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
179
Citations
3674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Godinez-Macias K, Chen D, Wallis J, Siegel M, Adam A, Bopp S, et al.
NPJ Drug Discov
. 2025 Mar;
2(1):3.
PMID: 40066064
Identification of novel drug targets is a key component of modern drug discovery. While antimalarial targets are often identified through the mechanism of action studies on phenotypically derived inhibitors, this...
2.
Gade P, Chang C, Pryde D, Fletcher D, Niven S, Godoy Magalhaes L, et al.
Eur J Med Chem
. 2025 Feb;
287:117335.
PMID: 39919438
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mt), is one of the deadliest infectious diseases. The rise of multidrug-resistant strains represents a major public health threat, requiring new therapeutic options. Bacterial...
3.
Godinez-Macias K, Chen D, Wallis J, Siegel M, Adam A, Bopp S, et al.
Res Sq
. 2024 Dec;
PMID: 39649165
The identification of novel drug targets for the purpose of designing small molecule inhibitors is key component to modern drug discovery. In malaria parasites, discoveries of antimalarial targets have primarily...
4.
Caldwell N, Peet C, Miller P, Colon B, Taylor M, Cocco M, et al.
Sci Transl Med
. 2024 Oct;
16(770):eadm8631.
PMID: 39441903
Cryptosporidiosis is a diarrheal disease caused by infection with spp. parasites and is a leading cause of death in malnourished children worldwide. The only approved treatment, nitazoxanide, has limited efficacy...
5.
Gruber F, Richardson A, Johnston Z, Myles R, Norcross N, Day D, et al.
PLoS One
. 2024 Feb;
19(2):e0297666.
PMID: 38377053
Male contraceptive options and infertility treatments are limited, and almost all innovation has been limited to updates to medically assisted reproduction protocols and methods. To accelerate the development of drugs...
6.
Wilson C, Gardner J, Gray D, Baragana B, Wyatt P, Cookson A, et al.
PLoS Negl Trop Dis
. 2023 Dec;
17(12):e0011799.
PMID: 38150490
There is a need for novel chemical matter for phenotypic and target-based screens to find starting points for drug discovery programmes in neglected infectious diseases and non-hormonal contraceptives that disproportionately...
7.
Webster L, Farrell S, Gilbert I, Wyatt P, Read K
ACS Med Chem Lett
. 2023 Nov;
14(11):1602.
PMID: 37970589
[This corrects the article DOI: 10.1021/acsmedchemlett.3c00215.].
8.
Green S, Wilson C, Eadsforth T, Punekar A, Tamaki F, Wood G, et al.
J Med Chem
. 2023 Nov;
66(22):15380-15408.
PMID: 37948640
There is an urgent need for new tuberculosis (TB) treatments, with novel modes of action, to reduce the incidence/mortality of TB and to combat resistance to current treatments. Through both...
9.
Bergkessel M, Forte B, Gilbert I
ACS Infect Dis
. 2023 Oct;
9(11):2062-2071.
PMID: 37819866
The need for new antibiotics is urgent. Antimicrobial resistance is rising, although currently, many more people die from drug-sensitive bacterial infections. The continued evolution of drug resistance is inevitable, fueled...
10.
Webster L, Farrell S, Gilbert I, Read K
ACS Med Chem Lett
. 2023 Aug;
14(8):1014-1016.
PMID: 37583828
Working in drug discovery is difficult for many institutions due to the need for resources, funding, and in-country expertise. The Wellcome Centre for Anti-Infective Research (WCAIR) is responding to the...